Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses the importance of measurable residual disease (MRD). Dr Fonseca describes the results of a study that found that patients with multiple myeloma (MM) who were MRD-positive had a similar outcome regardless of the type of response observed.
MRD in multiple myeloma: determining response
